pramipexole
Brand: Mirapex, Mirapex ER
Beers Criteria Prototype: levodopa-carbidopa
Drug Class: dopamine agonist
Drug Family: antiparkinsonian
Subclass: non-ergot D2/D3 dopamine receptor agonist
Organ Systems: cns
Mechanism of Action
Directly stimulates dopamine D2 and D3 receptors in the striatum and limbic system, bypassing the need for presynaptic dopamine synthesis. D3 receptor preference may contribute to antidepressant effects and response in restless legs syndrome. Does not require conversion by remaining dopaminergic neurons.
D2 dopamine receptorD3 dopamine receptor (high affinity)
Indications
- Parkinson's disease (early and advanced, as monotherapy or adjunct to levodopa)
- restless legs syndrome (moderate to severe)
Contraindications
- no absolute contraindications beyond hypersensitivity
Adverse Effects
Common
- nausea
- somnolence
- dizziness
- orthostatic hypotension
- peripheral edema
- hallucinations
Serious
- sudden onset sleep (sleep attacks; patient may fall asleep while driving)
- impulse control disorders (gambling, hypersexuality, binge eating)
- hallucinations and psychosis (higher risk in elderly)
- augmentation syndrome (in RLS)
Pharmacokinetics (ADME)
| Absorption | well absorbed orally; bioavailability >90%; food delays but does not reduce absorption |
| Distribution | protein binding ~15%; Vd ~500 L |
| Metabolism | minimal hepatic metabolism; primarily excreted unchanged |
| Excretion | renal (>90% unchanged); dose adjustment required in renal impairment |
| Half-life | 8-12 hours (IR); 12 hours (ER) |
| Onset | weeks for Parkinson's symptom improvement |
| Peak | 2 hours (IR); 6 hours (ER) |
| Duration | 8-12 hours (IR); 24 hours (ER) |
| Protein Binding | 15% |
| Vd | 500 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| dopamine antagonists (antipsychotics, metoclopramide) | pharmacodynamic antagonism; reduces pramipexole efficacy | major |
| cimetidine | reduces renal secretion of pramipexole; increases levels 50% | moderate |
| alcohol/CNS depressants | additive somnolence; increases risk of sleep attacks | moderate |
Nursing Considerations
- Warn patients about sudden-onset sleep (sleep attacks) that can occur without warning, particularly when driving; prohibit driving until tolerability is established.
- Assess for impulse control disorders at every visit: ask specifically about new gambling urges, increased sexual behavior, binge eating, or compulsive shopping — these may not be spontaneously reported.
- Orthostatic hypotension is prominent; measure BP lying and standing before and after dose titration; instruct patients to rise slowly.
- Renal dose adjustment is required; calculate CrCl before initiating and periodically; dose reduction proportional to degree of impairment.
Clinical Pearls
- Dopamine agonists are associated with impulse control disorders (ICDs) in up to 14% of patients; these ICDs (pathological gambling, hypersexuality, compulsive shopping, binge eating) are reversible on dose reduction or discontinuation and require systematic screening at every visit.
- Pramipexole's high D3 receptor affinity drives its efficacy in RLS; D3 receptors are concentrated in limbic areas involved in reward and sleep regulation, both relevant to RLS pathophysiology.
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.